CDT Equity notes Sarborg expansion into rare disease signature intelligence

CDT Equity (CDT) notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg announced that it has curated a database containing approximately 1,700 rare disease signatures, building upon its existing disease signature library of more than 1,600 conditions, as well as its agrochemical and bacterial signature datasets previously announced. According to Sarborg, structuring rare diseases as machine-interpretable biological signatures enables rapid analysis of disease relationships and potential therapeutic opportunities that would traditionally require extensive discovery and preclinical research. CDT has agreed a new collaboration with Sarborg to map CDT’s asset portfolio, including certain combination therapies, against this expanded rare disease database. CDT intends to use this data to maximize its IP position based on the outcome and to explore commercialization through external partnership opportunities. CDT holds a 20% equity stake in Sarborg and continues to utilize its cross-industry signature intelligence platform.